Tegaderm CHG IV Securement Dressing Reduces Catheter-Related Infections

The approval was based on data that showed using Tegaderm CHG IV Securement Dressing lowered CRBSI by 60%
The approval was based on data that showed using Tegaderm CHG IV Securement Dressing lowered CRBSI by 60%

3M announced that the Food and Drug Administration (FDA) has approved an expanded indication for Tegaderm CHG Chlorhexidine Gluconate IV Securement Dressing for the reduction of catheter-related bloodstream infections (CRBSI).

The FDA approval was based on data from a randomized, multi-arm, controlled clinical trial (n=1,879) that showed using Tegaderm CHG IV Securement Dressing lowered CRBSI by 60% in patients with central and arterial lines (0.5 per 1,000 days vs. 1.3 per 1,000 catheter-days; HR 0.402, 95% CI: 0.186–0.868 P=0.020) vs. non-CHG dressing. Upon catheter removal, there were decreases noted in catheter colonization and skin colonization rates. 

The Tegaderm CHG I.V. applied on a patient.

Tegaderm CHG IV Securement Dressing features a gel pad containing 2% w/w CHG, an antiseptic with broad-spectrum coverage against microbial and fungal pathogens with activity maintained for 10 days. Its transparent film and gel pad enables ongoing site observation to help detect complications at the insertion site. In addition, the design of the pad and dressing enable consistent application and secure catheter placement. 

For more information visit 3M.com.

Related Articles